ATR Antibody: The Anthrax toxin receptor (ATR) was initially discovered as the tumor endothelial marker 8 (TEM8). This protein, which exists in three isoforms (36, 40, and 60 kDa), is highly expressed in tumor vessels as well as in the vasculature of developing embryos, suggesting that it may normally play a role in angiogenesis. However, it also acts as the receptor for anthrax toxin. Following the binding of this protein by the protective antigen (PA) of anthrax, PA is cleaved and heptamerizes to form the binding site for both edema factor (EF) and lethal factor (LF). This complex is then endocytosed by the cell; acidification in endosomes allows the release of EF and LF into the cytoplasm where they interfere with MAPK signaling and induce apoptosis.
Immunogen
ATR antibody was raised against a peptide corresponding to 13 amino acids near the C-terminus of human ATR.The immunogen is located within the last 50 amino acids of ATR.
Application
ATR antibody can be used for detection of ATR by Western blot at 0.5 to 2 μg/mL. Antibody can also be used for immunocytochemistry starting at 2 μg/mL. For immunofluorescence start at 10 μg/mL.Antibody validated: Western Blot in human samples; Immunocytochemistry in human samples and Immunofluorescence in human samples. All other applications and species not yet tested.
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
